NM MPJE cheat sheet

The New Mexico Pharmacy Practice Act is codified at NMSA 1978, Chapter 61, Article 11; Board regulations are in Title 16, Chapter 19 NMAC.

The Board of Pharmacy licenses pharmacists, interns, technicians, and pharmacy sites and adopts rules implementing the Practice Act.

Board members are appointed by the Governor and include pharmacist and public representatives; meetings are subject to New Mexico's Open Meetings Act.

The Board may deny, suspend, revoke, or condition licenses, impose civil penalties, issue cease-and-desist orders, and require remediation.

Disciplinary grounds include fraud, incompetence, unprofessional conduct, impaired practice, criminal convictions affecting practice, and rule violations.

Board inspectors may inspect pharmacy premises and records; failure to cooperate can support discipline.

The New Mexico prescription monitoring program is administered through the Board and is used to review controlled substance dispensing.

Board rule violations can lead to discipline even when the conduct is not a criminal offense.

Pharmacist licensure requires graduation from an accredited program, passing NAPLEX and MPJE, completing Board-required internship hours, and a background check.

Pharmacy interns must be registered with the Board before performing intern duties and must work under an approved pharmacist preceptor.

Technicians must be registered with the Board; certified technician designation may require national certification and Board recognition.

Each pharmacy location must hold a New Mexico pharmacy license; ownership, location, or pharmacist-in-charge changes require Board notification or new licensure.

Licensees renew on the Board's assigned cycle, pay fees, and complete Board-required continuing education; certificates are retained for audit.

A complaint may proceed through investigation, notice, hearing, Board decision, and appeal; the Board may impose interim or summary action when authorized.

Licensees must notify the Board of changes required by rule, including address changes and certain criminal convictions.

The federal Controlled Substances Act places drugs in Schedules I-V; New Mexico's Controlled Substances Act, NMSA Chapter 30, Article 31, adopts and enforces state controls.

Schedule II prescriptions may not be refilled; emergency oral Schedule II orders require a written prescription within seven days.

Schedule III-V prescriptions may be refilled up to five times within six months of issue unless the prescriber limits refills.

Prescribers and dispensers need DEA registration; New Mexico pharmacies also need state pharmacy licensure and comply with Board controlled substance rules.

Controlled substance prescriptions require a legitimate medical purpose, prescriber DEA number, and compliance with schedule-specific rules.

Pharmacies take an initial inventory and biennial inventories; Schedule II records are maintained separately and readily retrievable.

Theft or significant loss of controlled substances must be reported to DEA and the Board as required, with documentation and corrective action.

Dispensers report controlled substance dispensing to the New Mexico PMP; pharmacists query the PMP when required to assess duplicative or unsafe therapy.

A prescription must include patient name and address, drug name, strength, dosage form, quantity, directions, date, prescriber identification, and refills.

Controlled substance prescriptions also require the prescriber's DEA number and must comply with schedule-specific refill and transmission rules.

Schedule II prescriptions cannot be refilled; Schedule III-V refills are limited to five within six months.

Oral prescriptions are permitted for most noncontrolled and Schedule III-V drugs; emergency oral Schedule II orders require written follow-up within seven days.

Schedule II prescriptions generally cannot be transferred for refill; Schedule III-V transfers require documentation under federal and state rules.

The label must show pharmacy name and address, Rx number, date, patient, directions, prescriber, drug, strength, quantity, and BUD or expiration.

Pharmacists must maintain prescription files and dispensing records and make them available for Board and DEA inspection.

Generic substitution is permitted unless the prescriber indicates dispensing as written, subject to New Mexico substitution law.

A pharmacist must offer counseling on each new prescription and whenever needed; the offer and any refusal should be documented.

Counseling includes drug name, purpose, directions, dose, side effects, interactions, storage, refill instructions, and adherence.

The pharmacist reviews the patient profile for allergies, duplicative therapy, interactions, contraindications, and dose appropriateness before dispensing.

Pharmaceutical care means accepting responsibility for drug therapy outcomes and identifying, resolving, and preventing drug therapy problems.

Counseling should occur in a private area; protected health information is disclosed only as permitted by HIPAA and state law.

Clinically significant interventions, adverse drug events, and medication errors should be documented and reported through quality processes.

Technicians may assist with medication history and administrative tasks but may not perform pharmacist counseling.

Collaborative practice agreements must be written and define delegated drug therapy management, communication, documentation, and monitoring.

New Mexico recognizes a pharmacist clinician credential for advanced practice; prescriptive authority depends on Board rules and collaborative agreements.

Pharmacists may administer vaccines under Board rules and protocols, maintain records, and report doses to the state immunization registry as required.

Drug wholesalers, manufacturers, and distributors must be appropriately licensed and comply with storage, recordkeeping, and tracing requirements.

Pharmacists may administer drugs other than vaccines only as authorized by law, protocol, or a valid prescription.

Facility and unit-dose distribution systems must maintain accountability, security, and records for drugs removed or administered.

Delegated administration and collaborative arrangements require patient identification, consent where required, and documentation in the patient record.

USP <795> governs nonsterile compounding: facility, equipment, master formulation records, compounding records, and beyond-use dates.

USP <797> governs sterile compounding: cleanroom classifications, environmental monitoring, personnel training, gowning, and BUD assignment.

USP <800> governs hazardous drugs: containment, engineering controls, PPE, deactivation, cleaning, spill control, and waste handling.

Compounded preparations must be patient-specific or permitted under limited office-use rules and may not simply copy commercially available products.

A beyond-use date is assigned from USP standards, stability, preservative, storage, and container; it may not exceed the applicable limit.

Quality assurance includes end-product checks, sterility and potency testing where required, complaint review, recall handling, and corrective action.

Compounding records must identify ingredients, sources, lot numbers, quantities, equipment, personnel, and final yield.

The pharmacy must maintain written compounding policies and training/competency records available for Board inspection.

Prescription, controlled substance, purchasing, and counseling records must be retained for the periods required by Board rule and federal law.

Board inspectors and DEA investigators may enter and inspect licensed pharmacy premises and required records.

DSCSA requires dispensers to receive and retain transaction information, verify suspect product, quarantine illegitimate product, and respond to recalls.

The FDCA prohibits misbranded or adulterated drugs; pharmacies must use legitimate suppliers and maintain recall and return records.

HIPAA requires safeguards, minimum necessary use and disclosure, patient rights, and breach notification for protected health information.

Controlled substances require initial and biennial inventories, separate Schedule II records, secure storage, and theft/loss reporting.

Pharmacies must maintain security controls, limit access to drug storage, and keep required licenses and registrations current.

Quality improvement programs should document medication errors, adverse events, and corrective actions.